Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Last updated: May 7, 2025
Sponsor: Masonic Cancer Center, University of Minnesota
Overall Status: Completed

Phase

N/A

Condition

Aplastic Anemia

Anemia

Telomere Related Diseases

Treatment

Stem Cell Transplant

Fludarabine

Cyclophosphamide

Clinical Study ID

NCT02162420
2013OC127
MT2013-34C
  • Ages < 70
  • All Genders

Study Summary

Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 0 - 70 years

  • Acceptable hematopoeitic stem cell donor

  • Dyskeratosis Congenita (DC) with evidence of BM failure defined as:

  • requirement for red blood cell and/or platelet transfusions or

  • requirement for G-CSF or GM-CSF or erythropoietin or

  • refractory cytopenias having one of the following three

  • platelets <50,000/uL or transfusion dependent

  • absolute neutrophil count <500/uL without hematopoietic growth factorsupport

  • hemoglobin <9g/uL or transfusion dependent

  • Diagnosis of DC with a triad of mucocutaneous features:

  • oral leukoplakia

  • nail dystrophy

  • abnormal reticular skin hyperpigmentation, or

  • Diagnosis of DC with one of the following:

  • short telomeres (under a research study)

  • mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1)

  • mutation in shelterin complex (TINF2)

  • mutation in telomere-capping complex (CTC1)

  • Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:

  • Refractory cytopenia defined by bone marrow cellularity <50% (with < 30%residual hematopoietic cells)

  • Diagnosis of SAA with refractory cytopenias having one of the following three:

  • platelets <20,000/uL or transfusion dependent

  • absolute neutrophil count <500/uL without hematopoietic growth factor support

  • absolute reticulocyte count <20,000/uL

  • Severe Aplastic Anemia (SAA) requiring a 2nd transplant

  • Graft failure as defined by blood/marrow chimerism of < 5%

  • Early myelodysplastic features

  • With or without clonal cytogenetic abnormalities

  • Adequate organ function defined as:

  • cardiac: left ventricular ejection fraction ≥ 35% with no evidence ofdecompensated heart failure

  • pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement

  • renal: Glomerular filtration rate (GFR) ≥30% predicted

  • Voluntary written consent

Exclusion

Exclusion Criteria:

  • Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis onbiopsy

  • Pregnant or lactating

  • Uncontrolled infection

  • Prior radiation therapy (applies to SAA patients only)

  • Diagnosis of Fanconi anemia based on DEB

  • Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with >30% blasts

Study Design

Total Participants: 61
Treatment Group(s): 6
Primary Treatment: Stem Cell Transplant
Phase:
Study Start date:
January 10, 2015
Estimated Completion Date:
March 11, 2025

Connect with a study center

  • University of Minnesota Medical Center, Fairview

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.